OncLive SOSS

Authors

Amy DeZern, MD, MHS, Sidney Kimmel Comprehensive Cancer Center

Latest:

Treatment Options in Myelodysplastic Syndromes

Javier Torres-Roca, MD

Latest:

Dr. Torres-Roca on Optimizing Radiation Therapy With GARD-Based Dosing in Oncology

Javier Torres-Roca, MD, discusses optimizing radiation therapy with genomic-adjusted radiation dose–based radiotherapy dosing in oncology.

Lisa Nodzon, PhD, APRN, AOCNP

Latest:

Clinical Perspectives: A 45-Year-Old Man With R/R CML

Panelists discuss a complex case of chronic myeloid leukemia (CML) progression in a younger patient, highlighting the critical importance of mutation testing, careful tyrosine kinase inhibitor (TKI) selection based on comorbidities, and adaptive treatment strategies to manage resistance and optimize outcomes.

Ami Umesh Badami, MD

Latest:

Dr Badami on the Optimal Selection of Second-Line TKIs in ccRCC

Ami Umesh Badami, MD, discusses clinical research that has informed treatment selection in the second-line clear cell renal cell carcinoma setting.

Harry Gill, MD, FRCP, FRCPath

Latest:

Dr Gill on the Efficacy and Genomic Features of Ropeginterferon Alfa-2B in Myelofibrosis

Harry Gill, MD, FRCP, FRCPath, discusses updated efficacy data and analysis of genomic characteristics for ropeginterferon alfa-2B in primary myelofibrosis.

Nikita Sinha, MD

Latest:

Dr. Sinha on the Antitumor Effects of Onvansertib in a Preclinical Endometroid Endometrial Cancer Model

Nikita Sinha, MD, discusses the potential effects of onvansertib on endometroid endometrial cancer pathogenesis in a preclinical model.

Craig Eckfeldt, MD, PhD

Latest:

Dr Eckfeldt on the Treatment Paradigm and Current Challenges in MDS

Craig Eckfeldt, MD, PhD, discusses the current treatment paradigm in MDS and the unmet needs in different subsets of patients.

Carrie Horton, MS, CGC

Latest:

Horton on Addressing the Equity Gap of Genetic Testing in Cancer Care

Carrie Horton, MS, CGC, discusses the importance of addressing the equity gap of genetic testing in cancer care.

Pavani Chalasani, MD, MPH

Latest:

Dr Chalasani on the Potential Utility of Eftilagimod Alpha in HER2–/HER2-Low Breast Cancer

Pavani Chalasani, MD, MPH, discusses the potential clinical significance of the AIPAC-003 trial of eftilagimod alpha in HER2–/HER2-low breast cancer.

Latest:

Dr Qin on Areas of Active and Future Investigation in NSCLC

Angel Qin, MD, discusses several areas of active investigation in non–small cell lung cancer, and highlights questions necessitating future research in this disease space.

Latest:

Real-World Treatment Reveals Discrepancy Between Actual Care and Clinical Trial Recommendations in MCL

A study of treatment patterns in adult patients with mantle cell lymphoma revealed a discrepancy between actual patterns of care and recommendations based on clinical trials.

Passi Janne, MD, PhD

Latest:

FLAURA2: Exploratory Overall Survival (OS) Analysis in Patients (Pts) with Poorer Prognostic Factors Treated with Osimertinib (Osi) ± Platinum-Pemetrexed Chemotherapy (CTx) as First-Line (1L) Treatment (Tx) for EGFR-Mutated (EGFRm) Advanced NSCLC

Lead presenter Passi Jaane, MD, PhD presents key data on the FLAURA2 trial presented at ESMO 2025.

Sailaja Kamaraju, MD

Barry W. Goy, MD

Barry W. Goy, MD, is a physician in the Department of Radiation Oncology at Kaiser Permanente.

Latest:

Dr Goy on Unclear Survival Benefit With Neoadjuvant ADT Plus EBRT in Intermediate-Risk Prostate Cancer

Barry W. Goy, MD, discusses 15-year survival outcomes with neoadjuvant androgen deprivation therapy plus EBRT in intermediate-risk prostate cancer.

Kathleen O’Brien

Latest:

The Desire to Always Do More

Jaffer A. Ajani, MD, has an unyielding drive that has resulted in breakthroughs in a deadly, but often overlooked, disease.

Marlana M. Orloff, MD

Marlana M. Orloff, MD, is an associate professor at Jefferson University and physician in the Department of Medical Oncology at Sidney Kimmel Cancer Center.

Latest:

Dr Orloff on OS Outcomes With Darovasertib Plus Crizotinib in Metastatic Uveal Melanoma

Marlana Orloff, MD, discusses efficacy findings with darovasertib plus crizotinib in metastatic uveal melanoma that were seen in the OptimUM-01 trial.

Annie Im, MD, FASCO

Latest:

Dr Annie Im: How to Treat Acute Myeloid Leukemia in 2024

Annie Im, MD, FASCO, University of Pittsburgh/UPMC Hillman Cancer Center, discusses the various modern approaches for the treatment of patients with acute myeloid leukemia.

Haeseong Park, MD, MPH

Latest:

Dr Park on the Combo of Epacadostat and Chemoradiation in Advanced Rectal Cancer

Haeseong Park, MD, MPH, discusses the rationale for combining epacadostat with preoperative chemoradiation in locally advanced rectal cancer.

Gordana Vunjak-Novakovic, PhD, BS, MS

Latest:

Dr. Vunjak-Novakovic on the Clinical Need for Personalizing Cancer Care

Gordana Vunjak-Novakovic, PhD, BS, MS, discusses the clinical need for personalizing cancer care.

Antonio Martin Jimenez Jimenez, MD

Latest:

Dr Jimenez Jimenez on the Clinical Implications of the ACCESS Trial in Hematological Malignancies

Antonio Martin Jimenez Jimenez, MD, discusses the clinical implications of PBSC from HLA-MMUD and PTCy for GVHD prophylaxis in hematological malignancies.